explorerTitle	Influenza Data Explorer
explorerSubtitle
selection	Northern Hemisphere	Southern Hemisphere
isPublished	false
thumbnail
hideAlertBanner	true
yAxisMin	0
hasMapTab	true
pickerColumnSlugs	Country
downloadDataLink
graphers
	title	subtitle	ySlugs	tableSlug	type	Confirmed cases or Symptoms Radio	Interval Radio	Metric Dropdown	Surveillance type Dropdown	timelineMinTime	selectedFacetStrategy	facetYDomain	hasMapTab	note	defaultView	tab	hideAnnotationFieldsInTitle
	Weekly share of influenza tests that were positive, all types of surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time.	pcnt_poscombined	flu_weekly	LineChart	Confirmed cases	Weekly	Share of positive tests (%)	All types of surveillance	-4043							true
	Monthly share of influenza tests that were positive	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time.	pcnt_poscombined	flu_monthly	LineChart	Confirmed cases	Monthly	Share of positive tests (%)	All types of surveillance	-4043					true	map	true
	Weekly share of influenza tests that were positive, sentinel surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time.	pcnt_possentinel	flu_weekly	LineChart	Confirmed cases	Weekly	Share of positive tests (%)	Sentinel surveillance	-4043				Sentinel sites collect data routinely from sites that are representative of the country's population.			true
	Monthly share of influenza tests that were positive, sentinel surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time.	pcnt_possentinel	flu_monthly	LineChart	Confirmed cases	Monthly	Share of positive tests (%)	Sentinel surveillance	-4043				Sentinel sites collect data routinely from sites that are representative of the country's population.			true
	Weekly share of influenza tests that were positive, non-sentinel surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time.	pcnt_posnonsentinel	flu_weekly	LineChart	Confirmed cases	Weekly	Share of positive tests (%)	Non-sentinel surveillance	-4043				Non-sentinel sites include data from multiple sources, including outbreak investigation, universal testing and testing at point of care.			true
	Monthly share of influenza tests that were positive, non-sentinel surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time.	pcnt_posnonsentinel	flu_monthly	LineChart	Confirmed cases	Monthly	Share of positive tests (%)	Non-sentinel surveillance	-4043				Non-sentinel sites include data from multiple sources, including outbreak investigation, universal testing and testing at point of care.			true
	Weekly share of influenza tests that were positive, undefined surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time.	pcnt_posnotdefined	flu_weekly	LineChart	Confirmed cases	Weekly	Share of positive tests (%)	Undefined surveillance	-4043				Undefined surveillance may include sentinel or non-sentinel sites or both.			true
	Monthly share of influenza tests that were positive, undefined surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time.	pcnt_posnotdefined	flu_monthly	LineChart	Confirmed cases	Monthly	Share of positive tests (%)	Undefined surveillance	-4043				Undefined surveillance may include sentinel or non-sentinel sites or both.			true
	Weekly confirmed cases of influenza (by strain)	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time.	ah1n12009combined_zfilled ah1combined_zfilled ah3combined_zfilled ah5combined_zfilled ah7n9combined_zfilled a_no_subtypecombined_zfilled bviccombined_zfilled byamcombined_zfilled bnotdeterminedcombined_zfilled	flu_weekly	StackedArea	Confirmed cases	Weekly	Confirmed cases (by strain)	All types of surveillance	-4043	entity	independent	false				true
	Monthly confirmed cases of influenza (by strain)	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time.	ah1n12009combined_zfilled ah1combined_zfilled ah3combined_zfilled ah5combined_zfilled ah7n9combined_zfilled a_no_subtypecombined_zfilled bviccombined_zfilled byamcombined_zfilled bnotdeterminedcombined_zfilled	flu_monthly	StackedArea	Confirmed cases	Monthly	Confirmed cases (by strain)	All types of surveillance	-4043	entity	independent	false				true
	Weekly confirmed cases of influenza (by strain)	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time.	ah1n12009sentinel_zfilled ah1sentinel_zfilled ah3sentinel_zfilled ah5sentinel_zfilled ah7n9sentinel_zfilled a_no_subtypesentinel_zfilled bvicsentinel_zfilled byamsentinel_zfilled bnotdeterminedsentinel_zfilled	flu_weekly	StackedArea	Confirmed cases	Weekly	Confirmed cases (by strain)	Sentinel surveillance	-4043	entity	independent	false	Sentinel sites collect data routinely from sites that are representative of the country's population.			true
	Monthly confirmed cases of influenza (by strain)	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time.	ah1n12009sentinel_zfilled ah1sentinel_zfilled ah3sentinel_zfilled ah5sentinel_zfilled ah7n9sentinel_zfilled a_no_subtypesentinel_zfilled bvicsentinel_zfilled byamsentinel_zfilled bnotdeterminedsentinel_zfilled	flu_monthly	StackedArea	Confirmed cases	Monthly	Confirmed cases (by strain)	Sentinel surveillance	-4043	entity	independent	false	Sentinel sites collect high-quality data in a timely manner systematically and routinely from sites representative of the population under surveillance.			true
	Weekly confirmed cases of influenza (by strain)	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time.	ah1n12009nonsentinel_zfilled ah1nonsentinel_zfilled ah3nonsentinel_zfilled ah5nonsentinel_zfilled ah7n9nonsentinel_zfilled a_no_subtypenonsentinel_zfilled bvicnonsentinel_zfilled byamnonsentinel_zfilled bnotdeterminednonsentinel_zfilled	flu_weekly	StackedArea	Confirmed cases	Weekly	Confirmed cases (by strain)	Non-sentinel surveillance	-4043	entity	independent	false	Non-sentinel sites include data from multiple sources, including outbreak investigation, universal testing and testing at point of care.			true
	Monthly confirmed cases of influenza (by strain)	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time.	ah1n12009nonsentinel_zfilled ah1nonsentinel_zfilled ah3nonsentinel_zfilled ah5nonsentinel_zfilled ah7n9nonsentinel_zfilled a_no_subtypenonsentinel_zfilled bvicnonsentinel_zfilled byamnonsentinel_zfilled bnotdeterminednonsentinel_zfilled	flu_monthly	StackedArea	Confirmed cases	Monthly	Confirmed cases (by strain)	Non-sentinel surveillance	-4043	entity	independent	false	Non-sentinel sites include data from multiple sources, including outbreak investigation, universal testing and testing at point of care.			true
	Weekly confirmed cases of influenza (by strain)	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time.	ah1n12009notdefined_zfilled ah1notdefined_zfilled ah3notdefined_zfilled ah5notdefined_zfilled ah7n9notdefined_zfilled a_no_subtypenotdefined_zfilled bvicnotdefined_zfilled byamnotdefined_zfilled bnotdeterminednotdefined_zfilled	flu_weekly	StackedArea	Confirmed cases	Weekly	Confirmed cases (by strain)	Undefined surveillance	-4043	entity	independent	false	Undefined surveillance may include sentinel or non-sentinel sites or both.			true
	Monthly confirmed cases of influenza (by strain)	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time.	ah1n12009notdefined_zfilled ah1notdefined_zfilled ah3notdefined_zfilled ah5notdefined_zfilled ah7n9notdefined_zfilled a_no_subtypenotdefined_zfilled bvicnotdefined_zfilled byamnotdefined_zfilled bnotdeterminednotdefined_zfilled	flu_monthly	StackedArea	Confirmed cases	Monthly	Confirmed cases (by strain)	Undefined surveillance	-4043	entity	independent	false	Undefined surveillance may include sentinel or non-sentinel sites or both.			true
	Weekly confirmed cases of influenza (by surveillance type)	This includes confirmed cases of all influenza strains. Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time.	inf_allcombined inf_allsentinel inf_allnonsentinel inf_allnotdefined	flu_weekly	LineChart	Confirmed cases	Weekly	Confirmed cases (by surveillance type)		-4043	metric	independent	false				true
	Monthly confirmed cases of influenza (by surveillance type)	This includes confirmed cases of all influenza strains. Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time.	inf_allcombined inf_allsentinel inf_allnonsentinel inf_allnotdefined	flu_monthly	LineChart	Confirmed cases	Monthly	Confirmed cases (by surveillance type)		-4043	metric	independent	false				true
	Weekly confirmed cases of influenza, all types of surveillance	This includes confirmed cases of all influenza strains. Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time.	inf_allcombined	flu_weekly	LineChart	Confirmed cases	Weekly	All strains	All types of surveillance	-4043							true
	Monthly confirmed cases of influenza, all types of surveillance	This includes confirmed cases of all influenza strains. Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time.	inf_allcombined	flu_monthly	LineChart	Confirmed cases	Monthly	All strains	All types of surveillance	-4043							true
	Weekly confirmed cases of influenza, sentinel surveillance	This includes confirmed cases of all influenza strains. Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time.	inf_allsentinel	flu_weekly	LineChart	Confirmed cases	Weekly	All strains	Sentinel surveillance	-4043				Sentinel sites collect data routinely from sites that are representative of the country's population.			true
	Monthly confirmed cases of, sentinel surveillance	This includes confirmed cases of all influenza strains. Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time.	inf_allsentinel	flu_monthly	LineChart	Confirmed cases	Monthly	All strains	Sentinel surveillance	-4043				Sentinel sites collect data routinely from sites that are representative of the country's population.			true
	Weekly confirmed cases of influenza, non-sentinel surveillance	This includes confirmed cases of all influenza strains. Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time.	inf_allnonsentinel	flu_weekly	LineChart	Confirmed cases	Weekly	All strains	Non-sentinel surveillance	-4043				Non-sentinel sites include data from multiple sources, including outbreak investigation, universal testing and testing at point of care.			true
	Monthly confirmed cases of influenza, non-sentinel surveillance	This includes confirmed cases of all influenza strains. Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time.	inf_allnonsentinel	flu_monthly	LineChart	Confirmed cases	Monthly	All strains	Non-sentinel surveillance	-4043				Non-sentinel sites include data from multiple sources, including outbreak investigation, universal testing and testing at point of care.			true
	Weekly confirmed cases of influenza, undefined surveillance	This includes confirmed cases of all influenza strains. Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time.	inf_allnotdefined	flu_weekly	LineChart	Confirmed cases	Weekly	All strains	Undefined surveillance	-4043				Undefined surveillance may include sentinel or non-sentinel sites or both.			true
	Monthly confirmed cases of influenza, undefined surveillance	This includes confirmed cases of all influenza strains. Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time.	inf_allnotdefined	flu_monthly	LineChart	Confirmed cases	Monthly	All strains	Undefined surveillance	-4043				Undefined surveillance may include sentinel or non-sentinel sites or both.			true
	Weekly comparison of data on respiratory infections	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time.	reported_ari_cases reported_ili_cases reported_sari_cases	flu_weekly	LineChart	Symptoms	Weekly	Comparison of data on respiratory infections		-4043	metric	independent	false	Acute respiratory illnesses are defined by the WHO as sudden/acute onset of ≥1 of the following symptoms: cough, sore throat, shortness of breath, coryza; and were judged by a clinician to be due to an infection. Influenza-like illnesses refer to acute respiratory infections with a fever ≥38ºC, a cough, and onset of symptoms within the last 10 days. Severe acute respiratory infections refer to serious cases of influenza-like illnesses which require hospitalization.			true
	Monthly comparison of data on respiratory infections	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time.	reported_ari_cases reported_ili_cases reported_sari_cases	flu_monthly	LineChart	Symptoms	Weekly	Comparison of data on respiratory infections		-4043	metric	independent	false	Acute respiratory illnesses are defined by the WHO as sudden/acute onset of ≥1 of the following symptoms: cough, sore throat, shortness of breath, coryza; and were judged by a clinician to be due to an infection. Influenza-like illnesses refer to acute respiratory infections with a fever ≥38ºC, a cough, and onset of symptoms within the last 10 days. Severe acute respiratory infections refer to serious cases of influenza-like illnesses which require hospitalization.			true
	Weekly reported cases of influenza-like illnesses	Influenza-like illnesses are defined by the WHO as acute respiratory infections with a fever ≥38ºC, a cough, and onset of symptoms within the last 10 days.	reported_ili_cases	flu_weekly	LineChart	Symptoms	Weekly	Influenza-like illnesses		-4043				Influenza-like illnesses refer to acute respiratory infections with a fever ≥38ºC, a cough, and onset of symptoms within the last 10 days.			true
	Monthly reported cases of influenza-like illnesses	Influenza-like illnesses are defined by the WHO as acute respiratory infections with a fever ≥38ºC, a cough, and onset of symptoms within the last 10 days.	reported_ili_cases	flu_monthly	LineChart	Symptoms	Monthly	Influenza-like illnesses		-4043				Influenza-like illnesses refer to acute respiratory infections with a fever ≥38ºC, a cough, and onset of symptoms within the last 10 days.			true
	Weekly reported cases of acute respiratory infections	Acute respiratory illnesses are defined by the WHO as sudden/acute onset of ≥1 of the following symptoms: cough, sore throat, shortness of breath, coryza; and were judged by a clinician to be due to an infection.	reported_ari_cases	flu_weekly	LineChart	Symptoms	Weekly	Acute respiratory infections		-4043				Acute respiratory illnesses are defined by the WHO as sudden/acute onset of ≥1 of the following symptoms: cough, sore throat, shortness of breath, coryza; and were judged by a clinician to be due to an infection.			true
	Monthly reported cases of acute respiratory infections	Acute respiratory illnesses are defined by the WHO as sudden/acute onset of ≥1 of the following symptoms: cough, sore throat, shortness of breath, coryza; and were judged by a clinician to be due to an infection.	reported_ari_cases	flu_monthly	LineChart	Symptoms	Monthly	Acute respiratory infections		-4043				Acute respiratory illnesses are defined by the WHO as sudden/acute onset of ≥1 of the following symptoms: cough, sore throat, shortness of breath, coryza; and were judged by a clinician to be due to an infection.			true
	Weekly reported cases of severe acute respiratory infections	Severe acute respiratory illnesses are defined by the WHO as acute respiratory infections with history of fever or measured fever of ≥ 38 C°, cough, with onset within the last 10 days, and which require hospitalization.	reported_sari_cases	flu_weekly	LineChart	Symptoms	Weekly	Severe acute respiratory infections		-4043				Severe acute respiratory infections refer to serious cases of influenza-like illnesses which require hospitalization.			true
	Monthly reported cases of severe acute respiratory infections	Severe acute respiratory illnesses are defined by the WHO as acute respiratory infections with history of fever or measured fever of ≥ 38 C°, cough, with onset within the last 10 days, and which require hospitalization.	reported_sari_cases	flu_monthly	LineChart	Symptoms	Monthly	Severe acute respiratory infections		-4043				Severe acute respiratory infections refer to serious cases of influenza-like illnesses which require hospitalization.			true
	Weekly confirmed cases of influenza A, sentinel surveillance	This includes confirmed cases of all strains of influenza A virus. Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time.	inf_asentinel	flu_weekly	LineChart	Confirmed cases	Weekly	All influenza A	Sentinel surveillance	-4043				Sentinel sites collect data routinely from sites that are representative of the country's population.			true
	Monthly confirmed cases of influenza A, sentinel surveillance	This includes confirmed cases of all strains of influenza A virus. Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time.	inf_asentinel	flu_monthly	LineChart	Confirmed cases	Monthly	All influenza A	Sentinel surveillance	-4043				Sentinel sites collect data routinely from sites that are representative of the country's population.			true
	Weekly confirmed cases of influenza A, non-sentinel surveillance	This includes confirmed cases of all strains of influenza A virus. Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time.	inf_anonsentinel	flu_weekly	LineChart	Confirmed cases	Weekly	All influenza A	Non-sentinel surveillance	-4043				Non-sentinel sites include data from multiple sources, including outbreak investigation, universal testing and testing at point of care.			true
	Monthly confirmed cases of influenza A, non-sentinel surveillance	This includes confirmed cases of all strains of influenza A virus. Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time.	inf_anonsentinel	flu_monthly	LineChart	Confirmed cases	Monthly	All influenza A	Non-sentinel surveillance	-4043				Non-sentinel sites include data from multiple sources, including outbreak investigation, universal testing and testing at point of care.			true
	Weekly confirmed cases of influenza A, undefined surveillance	This includes confirmed cases of all strains of influenza A virus. Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time.	inf_anotdefined	flu_weekly	LineChart	Confirmed cases	Weekly	All influenza A	Undefined surveillance	-4043				Undefined surveillance may include sentinel or non-sentinel sites or both.			true
	Monthly confirmed cases of influenza A, undefined surveillance	This includes confirmed cases of all strains of influenza A virus. Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time.	inf_anotdefined	flu_monthly	LineChart	Confirmed cases	Monthly	All influenza A	Undefined surveillance	-4043				Undefined surveillance may include sentinel or non-sentinel sites or both.			true
	Weekly confirmed cases of influenza A, all types of surveillance	This includes confirmed cases of all strains of influenza A virus. Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time.	inf_acombined	flu_weekly	LineChart	Confirmed cases	Weekly	All influenza A	All types of surveillance	-4043							true
	Monthly confirmed cases of influenza A, all types of surveillance	This includes confirmed cases of all strains of influenza A virus. Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time.	inf_acombined	flu_monthly	LineChart	Confirmed cases	Monthly	All influenza A	All types of surveillance	-4043							true
	Weekly confirmed cases of influenza A H1N1 (2009), sentinel surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to have a strain of influenza A virus related to the H1N1 ("Swine flu") pandemic that emerged in 2009.	ah1n12009sentinel	flu_weekly	LineChart	Confirmed cases	Weekly	Influenza A H1N12009	Sentinel surveillance	-4043				Sentinel sites collect data routinely from sites that are representative of the country's population.			true
	Monthly confirmed cases of influenza A H1N1 (2009), sentinel surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to have a strain of influenza A virus related to the H1N1 ("Swine flu") pandemic that emerged in 2009.	ah1n12009sentinel	flu_monthly	LineChart	Confirmed cases	Monthly	Influenza A H1N12009	Sentinel surveillance	-4043				Sentinel sites collect data routinely from sites that are representative of the country's population.			true
	Weekly confirmed cases of influenza A H1N1 (2009), non-sentinel surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to have a strain of influenza A virus related to the H1N1 ("Swine flu") pandemic that emerged in 2009.	ah1n12009nonsentinel	flu_weekly	LineChart	Confirmed cases	Weekly	Influenza A H1N12009	Non-sentinel surveillance	-4043				Non-sentinel sites include data from multiple sources, including outbreak investigation, universal testing and testing at point of care.			true
	Monthly confirmed cases of influenza A H1N1 (2009), non-sentinel surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to have a strain of influenza A virus related to the H1N1 ("Swine flu") pandemic that emerged in 2009.	ah1n12009nonsentinel	flu_monthly	LineChart	Confirmed cases	Monthly	Influenza A H1N12009	Non-sentinel surveillance	-4043				Non-sentinel sites include data from multiple sources, including outbreak investigation, universal testing and testing at point of care.			true
	Weekly confirmed cases of influenza A H1N1 (2009), undefined surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to have a strain of influenza A virus related to the H1N1 ("Swine flu") pandemic that emerged in 2009.	ah1n12009notdefined	flu_weekly	LineChart	Confirmed cases	Weekly	Influenza A H1N12009	Undefined surveillance	-4043				Undefined surveillance may include sentinel or non-sentinel sites or both.			true
	Monthly confirmed cases of influenza A H1N1 (2009), undefined surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to have a strain of influenza A virus related to the H1N1 ("Swine flu") pandemic that emerged in 2009.	ah1n12009combined	flu_monthly	LineChart	Confirmed cases	Monthly	Influenza A H1N12009	Undefined surveillance	-4043				Undefined surveillance may include sentinel or non-sentinel sites or both.			true
	Weekly confirmed cases of influenza A H1N1 (2009), all types of surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to have a strain of influenza A virus related to the H1N1 ("Swine flu") pandemic that emerged in 2009.	ah1n12009combined	flu_weekly	LineChart	Confirmed cases	Weekly	Influenza A H1N12009	All types of surveillance	-4043							true
	Monthly confirmed cases of influenza A H1N1 (2009), all types of surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to have a strain of influenza A virus related to the H1N1 ("Swine flu") pandemic that emerged in 2009.	ah1n12009combined	flu_monthly	LineChart	Confirmed cases	Monthly	Influenza A H1N12009	All types of surveillance	-4043							true
	Weekly confirmed cases of influenza A H1, sentinel surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be of the H1 strain of influenza A virus.	ah1sentinel	flu_weekly	LineChart	Confirmed cases	Weekly	Influenza A H1	Sentinel surveillance	-4043				Sentinel sites collect data routinely from sites that are representative of the country's population.			true
	Monthly confirmed cases of influenza A H1, sentinel surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be of the H1 strain of influenza A virus.	ah1sentinel	flu_monthly	LineChart	Confirmed cases	Monthly	Influenza A H1	Sentinel surveillance	-4043				Sentinel sites collect data routinely from sites that are representative of the country's population.			true
	Weekly confirmed cases of influenza A H1, non-sentinel surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be of the H1 strain of influenza A virus.	ah1nonsentinel	flu_weekly	LineChart	Confirmed cases	Weekly	Influenza A H1	Non-sentinel surveillance	-4043				Non-sentinel sites include data from multiple sources, including outbreak investigation, universal testing and testing at point of care.			true
	Monthly confirmed cases of influenza A H1, non-sentinel surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be of the H1 strain of influenza A virus.	ah1nonsentinel	flu_monthly	LineChart	Confirmed cases	Monthly	Influenza A H1	Non-sentinel surveillance	-4043				Non-sentinel sites include data from multiple sources, including outbreak investigation, universal testing and testing at point of care.			true
	Weekly confirmed cases of influenza A H1, undefined surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be of the H1 strain of influenza A virus.	ah1notdefined	flu_weekly	LineChart	Confirmed cases	Weekly	Influenza A H1	Undefined surveillance	-4043				Undefined surveillance may include sentinel or non-sentinel sites or both.			true
	Monthly confirmed cases of influenza A H1, undefined surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be of the H1 strain of influenza A virus.	ah1notdefined	flu_monthly	LineChart	Confirmed cases	Monthly	Influenza A H1	Undefined surveillance	-4043				Undefined surveillance may include sentinel or non-sentinel sites or both.			true
	Weekly confirmed cases of influenza A H1, all types of surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be of the H1 strain of influenza A virus.	ah1combined	flu_weekly	LineChart	Confirmed cases	Weekly	Influenza A H1	All types of surveillance	-4043							true
	Monthly confirmed cases of influenza A H1, all types of surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be of the H1 strain of influenza A virus.	ah1combined	flu_monthly	LineChart	Confirmed cases	Monthly	Influenza A H1	All types of surveillance	-4043							true
	Weekly confirmed cases of influenza A H3, sentinel surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be of the H3 strain of influenza A virus.	ah3sentinel	flu_weekly	LineChart	Confirmed cases	Weekly	Influenza A H3	Sentinel surveillance	-4043				Sentinel sites collect data routinely from sites that are representative of the country's population.			true
	Monthly confirmed cases of influenza A H3, sentinel surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be of the H3 strain of influenza A virus.	ah3sentinel	flu_monthly	LineChart	Confirmed cases	Monthly	Influenza A H3	Sentinel surveillance	-4043				Sentinel sites collect data routinely from sites that are representative of the country's population.			true
	Weekly confirmed cases of influenza A H3, non-sentinel surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be of the H3 strain of influenza A virus.	ah3nonsentinel	flu_weekly	LineChart	Confirmed cases	Weekly	Influenza A H3	Non-sentinel surveillance	-4043				Non-sentinel sites include data from multiple sources, including outbreak investigation, universal testing and testing at point of care.			true
	Monthly confirmed cases of influenza A H3, non-sentinel surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be of the H3 strain of influenza A virus.	ah3nonsentinel	flu_monthly	LineChart	Confirmed cases	Monthly	Influenza A H3	Non-sentinel surveillance	-4043				Non-sentinel sites include data from multiple sources, including outbreak investigation, universal testing and testing at point of care.			true
	Weekly confirmed cases of influenza A H3, undefined surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be of the H3 strain of influenza A virus.	ah3notdefined	flu_weekly	LineChart	Confirmed cases	Weekly	Influenza A H3	Undefined surveillance	-4043				Undefined surveillance may include sentinel or non-sentinel sites or both.			true
	Monthly confirmed cases of influenza A H3, undefined surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be of the H3 strain of influenza A virus.	ah3notdefined	flu_monthly	LineChart	Confirmed cases	Monthly	Influenza A H3	Undefined surveillance	-4043				Undefined surveillance may include sentinel or non-sentinel sites or both.			true
	Weekly confirmed cases of influenza A H3, all types of surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be of the H3 strain of influenza A virus.	ah3combined	flu_weekly	LineChart	Confirmed cases	Weekly	Influenza A H3	All types of surveillance	-4043							true
	Monthly confirmed cases of influenza A H3, all types of surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be of the H3 strain of influenza A virus.	ah3combined	flu_monthly	LineChart	Confirmed cases	Monthly	Influenza A H3	All types of surveillance	-4043							true
	Weekly confirmed cases of influenza A H5, sentinel surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be of the H5 strain of influenza A virus.	ah5sentinel	flu_weekly	LineChart	Confirmed cases	Weekly	Influenza A H5	Sentinel surveillance	-4043				Sentinel sites collect data routinely from sites that are representative of the country's population.			true
	Monthly confirmed cases of influenza A H5, sentinel surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be of the H5 strain of influenza A virus.	ah5sentinel	flu_monthly	LineChart	Confirmed cases	Monthly	Influenza A H5	Sentinel surveillance	-4043				Sentinel sites collect data routinely from sites that are representative of the country's population.			true
	Weekly confirmed cases of influenza A H5, non-sentinel surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be of the H5 strain of influenza A virus.	ah5nonsentinel	flu_weekly	LineChart	Confirmed cases	Weekly	Influenza A H5	Non-sentinel surveillance	-4043				Non-sentinel sites include data from multiple sources, including outbreak investigation, universal testing and testing at point of care.			true
	Monthly confirmed cases of influenza A H5, non-sentinel surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be of the H5 strain of influenza A virus.	ah5nonsentinel	flu_monthly	LineChart	Confirmed cases	Monthly	Influenza A H5	Non-sentinel surveillance	-4043				Non-sentinel sites include data from multiple sources, including outbreak investigation, universal testing and testing at point of care.			true
	Weekly confirmed cases of influenza A H5, undefined surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be of the H5 strain of influenza A virus.	ah5notdefined	flu_weekly	LineChart	Confirmed cases	Weekly	Influenza A H5	Undefined surveillance	-4043				Undefined surveillance may include sentinel or non-sentinel sites or both.			true
	Weekly confirmed cases of influenza A H5, all types of surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be of the H5 strain of influenza A virus.	ah5combined	flu_weekly	LineChart	Confirmed cases	Weekly	Influenza A H5	All types of surveillance	-4043							true
	Weekly confirmed cases of influenza A H7N9, sentinel surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be of the H7N9 strain of influenza A virus.	ah7n9sentinel	flu_weekly	LineChart	Confirmed cases	Weekly	Influenza A H7N9	Sentinel surveillance	-4043				Sentinel sites collect data routinely from sites that are representative of the country's population.			true
	Weekly confirmed cases of influenza A H7N9, non-sentinel surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be of the H7N9 strain of influenza A virus.	ah7n9nonsentinel	flu_weekly	LineChart	Confirmed cases	Weekly	Influenza A H7N9	Non-sentinel surveillance	-4043				Non-sentinel sites include data from multiple sources, including outbreak investigation, universal testing and testing at point of care.			true
	Weekly confirmed cases of influenza A H7N9, non-sentinel surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be of the H7N9 strain of influenza A virus.	ah7n9notdefined	flu_weekly	LineChart	Confirmed cases	Weekly	Influenza A H7N9	Undefined surveillance	-4043				Undefined surveillance may include sentinel or non-sentinel sites or both.			true
	Weekly confirmed cases of influenza A H7N9, all types of surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their subtype. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be of the H7N9 strain of influenza A virus.	ah7n9combined	flu_weekly	LineChart	Confirmed cases	Weekly	Influenza A H7N9	All types of surveillance	-4043							true
	Weekly confirmed cases of influenza A (unknown subtype), sentinel surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be influenza A virus, but their subtype was not confirmed.	a_no_subtypesentinel	flu_weekly	LineChart	Confirmed cases	Weekly	Influenza A unknown	Sentinel surveillance	-4043				Sentinel sites collect data routinely from sites that are representative of the country's population.			true
	Weekly confirmed cases of influenza A (unknown subtype), non-sentinel surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be influenza A virus, but their subtype was not confirmed.	a_no_subtypenonsentinel	flu_weekly	LineChart	Confirmed cases	Weekly	Influenza A unknown	Non-sentinel surveillance	-4043				Non-sentinel sites include data from multiple sources, including outbreak investigation, universal testing and testing at point of care.			true
	Weekly confirmed cases of influenza A (unknown subtype), undefined surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be influenza A virus, but their subtype was not confirmed.	a_no_subtypenotdefined	flu_weekly	LineChart	Confirmed cases	Weekly	Influenza A unknown	Undefined surveillance	-4043				Undefined surveillance may include sentinel or non-sentinel sites or both.			true
	Weekly confirmed cases of influenza A (unknown subtype), all types of surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be influenza A virus, but their subtype was not confirmed.	a_no_subtypecombined	flu_weekly	LineChart	Confirmed cases	Weekly	Influenza A unknown	All types of surveillance	-4043							true
	Weekly confirmed cases of influenza B, sentinel surveillance	This includes confirmed cases of all strains of influenza B virus. Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time.	inf_bsentinel	flu_weekly	LineChart	Confirmed cases	Weekly	All influenza B	Sentinel surveillance	-4043				Sentinel sites collect data routinely from sites that are representative of the country's population.			true
	Weekly confirmed cases of influenza B, non-sentinel surveillance	This includes confirmed cases of all strains of influenza B virus. Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time.	inf_bnonsentinel	flu_weekly	LineChart	Confirmed cases	Weekly	All influenza B	Non-sentinel surveillance	-4043				Non-sentinel sites include data from multiple sources, including outbreak investigation, universal testing and testing at point of care.			true
	Weekly confirmed cases of influenza B, undefined surveillance	This includes confirmed cases of all strains of influenza B virus. Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time.	inf_bnotdefined	flu_weekly	LineChart	Confirmed cases	Weekly	All influenza B	Undefined surveillance	-4043				Undefined surveillance may include sentinel or non-sentinel sites or both.			true
	Weekly confirmed cases of influenza B, all types of surveillance	This includes confirmed cases of all strains of influenza B virus. Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time.	inf_bcombined	flu_weekly	LineChart	Confirmed cases	Weekly	All influenza B	All types of surveillance	-4043							true
	Weekly confirmed cases of influenza B Yamagata, sentinel surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be of the Yamagata lineage of influenza B virus.	byamsentinel	flu_weekly	LineChart	Confirmed cases	Weekly	Influenza B Yamagata	Sentinel surveillance	-4043				Sentinel sites collect data routinely from sites that are representative of the country's population.			true
	Weekly confirmed cases of influenza B Yamagata, non-sentinel surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be of the Yamagata lineage of influenza B virus.	byamnonsentinel	flu_weekly	LineChart	Confirmed cases	Weekly	Influenza B Yamagata	Non-sentinel surveillance	-4043				Non-sentinel sites include data from multiple sources, including outbreak investigation, universal testing and testing at point of care.			true
	Weekly confirmed cases of influenza B Yamagata, undefined surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be of the Yamagata lineage of influenza B virus.	byamnotdefined	flu_weekly	LineChart	Confirmed cases	Weekly	Influenza B Yamagata	Undefined surveillance	-4043				Undefined surveillance may include sentinel or non-sentinel sites or both.			true
	Weekly confirmed cases of influenza B Yamagata, all types of surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be of the Yamagata lineage of influenza B virus.	byamcombined	flu_weekly	LineChart	Confirmed cases	Weekly	Influenza B Yamagata	All types of surveillance	-4043							true
	Weekly confirmed cases of influenza B Victoria, sentinel surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be of the Victoria lineage of influenza B virus.	bvicsentinel	flu_weekly	LineChart	Confirmed cases	Weekly	Influenza B Victoria	Sentinel surveillance	-4043				Sentinel sites collect data routinely from sites that are representative of the country's population.			true
	Weekly confirmed cases of influenza B Victoria, non-sentinel surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be of the Victoria lineage of influenza B virus.	bvicnonsentinel	flu_weekly	LineChart	Confirmed cases	Weekly	Influenza B Victoria	Non-sentinel surveillance	-4043				Non-sentinel sites include data from multiple sources, including outbreak investigation, universal testing and testing at point of care.			true
	Weekly confirmed cases of influenza B Victoria, undefined surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be of the Victoria lineage of influenza B virus.	bvicnotdefined	flu_weekly	LineChart	Confirmed cases	Weekly	Influenza B Victoria	Undefined surveillance	-4043				Undefined surveillance may include sentinel or non-sentinel sites or both.			true
	Weekly confirmed cases of influenza B Victoria, all types of surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be of the Victoria lineage of influenza B virus.	bviccombined	flu_weekly	LineChart	Confirmed cases	Weekly	Influenza B Victoria	All types of surveillance	-4043							true
	Weekly confirmed cases of influenza B (unknown subtype), sentinel surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be influenza B virus, but their lineage was not determined.	bnotdeterminedsentinel	flu_weekly	LineChart	Confirmed cases	Weekly	Influenza B unknown	Sentinel surveillance	-4043				Sentinel sites collect data routinely from sites that are representative of the country's population.			true
	Weekly confirmed cases of influenza B (unknown subtype), non-sentinel surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be influenza B virus, but their lineage was not determined.	bnotdeterminednonsentinel	flu_weekly	LineChart	Confirmed cases	Weekly	Influenza B unknown	Non-sentinel surveillance	-4043				Non-sentinel sites include data from multiple sources, including outbreak investigation, universal testing and testing at point of care.			true
	Weekly confirmed cases of influenza B (unknown subtype)	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be influenza B virus, but their lineage was not determined.	bnotdeterminednotdefined	flu_weekly	LineChart	Confirmed cases	Weekly	Influenza B unknown	Undefined surveillance	-4043				Undefined surveillance may include sentinel or non-sentinel sites or both.			true
	Weekly confirmed cases of influenza B (unknown subtype), all types of surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be influenza B virus, but their lineage was not determined.	bnotdeterminedcombined	flu_weekly	LineChart	Confirmed cases	Weekly	Influenza B unknown	All types of surveillance	-4043							true
	Weekly confirmed cases of influenza A H5, undefined surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be of the H5 strain of influenza A virus.	ah5notdefined	flu_monthly	LineChart	Confirmed cases	Monthly	Influenza A H5	Undefined surveillance	-4043				Undefined surveillance may include sentinel or non-sentinel sites or both.			true
	Monthly confirmed cases of influenza A H5, all types of surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be of the H5 strain of influenza A virus.	ah5combined	flu_monthly	LineChart	Confirmed cases	Monthly	Influenza A H5	All types of surveillance	-4043							true
	Monthly confirmed cases of influenza A H7N9, sentinel surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be of the H7N9 strain of influenza A virus.	ah7n9sentinel	flu_monthly	LineChart	Confirmed cases	Monthly	Influenza A H7N9	Sentinel surveillance	-4043				Sentinel sites collect data routinely from sites that are representative of the country's population.			true
	Monthly confirmed cases of influenza A H7N9, non-sentinel surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be of the H7N9 strain of influenza A virus.	ah7n9nonsentinel	flu_monthly	LineChart	Confirmed cases	Monthly	Influenza A H7N9	Non-sentinel surveillance	-4043				Non-sentinel sites include data from multiple sources, including outbreak investigation, universal testing and testing at point of care.			true
	Monthly confirmed cases of influenza A H7N9, undefined surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be of the H7N9 strain of influenza A virus.	ah7n9notdefined	flu_monthly	LineChart	Confirmed cases	Monthly	Influenza A H7N9	Undefined surveillance	-4043				Undefined surveillance may include sentinel or non-sentinel sites or both.			true
	Monthly confirmed cases of influenza A H7N9, all types of surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be of the H7N9 strain of influenza A virus.	ah7n9combined	flu_monthly	LineChart	Confirmed cases	Monthly	Influenza A H7N9	All types of surveillance	-4043							true
	Monthly confirmed cases of influenza A (unknown subtype), sentinel surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be influenza A virus, but their subtype was not confirmed.	a_no_subtypesentinel	flu_monthly	LineChart	Confirmed cases	Monthly	Influenza A unknown	Sentinel surveillance	-4043				Sentinel sites collect data routinely from sites that are representative of the country's population.			true
	Monthly confirmed cases of influenza A (unknown subtype), non-sentinel surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be influenza A virus, but their subtype was not confirmed.	a_no_subtypenonsentinel	flu_monthly	LineChart	Confirmed cases	Monthly	Influenza A unknown	Non-sentinel surveillance	-4043				Non-sentinel sites include data from multiple sources, including outbreak investigation, universal testing and testing at point of care.			true
	Monthly confirmed cases of influenza A (unknown subtype), undefined surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be influenza A virus, but their subtype was not confirmed.	a_no_subtypenotdefined	flu_monthly	LineChart	Confirmed cases	Monthly	Influenza A unknown	Undefined surveillance	-4043				Undefined surveillance may include sentinel or non-sentinel sites or both.			true
	Monthly confirmed cases of influenza A (unknown subtype), all types of surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be influenza A virus, but their subtype was not confirmed.	a_no_subtypecombined	flu_monthly	LineChart	Confirmed cases	Monthly	Influenza A unknown	All types of surveillance	-4043							true
	Monthly confirmed cases of influenza B, sentinel surveillance	This includes confirmed cases of any lineage of influenza B virus. Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their lineage.	inf_bsentinel	flu_monthly	LineChart	Confirmed cases	Monthly	All influenza B	Sentinel surveillance	-4043				Sentinel sites collect data routinely from sites that are representative of the country's population.			true
	Monthly confirmed cases of influenza B, non-sentinel surveillance	This includes confirmed cases of any lineage of influenza B virus. Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their lineage.	inf_bnonsentinel	flu_monthly	LineChart	Confirmed cases	Monthly	All influenza B	Non-sentinel surveillance	-4043				Non-sentinel sites include data from multiple sources, including outbreak investigation, universal testing and testing at point of care.			true
	Monthly confirmed cases of influenza B, undefined surveillance	This includes confirmed cases of any lineage of influenza B virus. Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their lineage.	inf_bnotdefined	flu_monthly	LineChart	Confirmed cases	Monthly	All influenza B	Undefined surveillance	-4043				Undefined surveillance may include sentinel or non-sentinel sites or both.			true
	Monthly confirmed cases of influenza B, all types of surveillance	This includes confirmed cases of any lineage of influenza B virus. Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their lineage.	inf_bcombined	flu_monthly	LineChart	Confirmed cases	Monthly	All influenza B	All types of surveillance	-4043							true
	Monthly confirmed cases of influenza B Yamagata, sentinel surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be of the Yamagata lineage of influenza B virus.	byamsentinel	flu_monthly	LineChart	Confirmed cases	Monthly	Influenza B Yamagata	Sentinel surveillance	-4043				Sentinel sites collect data routinely from sites that are representative of the country's population.			true
	Monthly confirmed cases of influenza B Yamagata, non-sentinel surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be of the Yamagata lineage of influenza B virus.	byamnonsentinel	flu_monthly	LineChart	Confirmed cases	Monthly	Influenza B Yamagata	Non-sentinel surveillance	-4043				Non-sentinel sites include data from multiple sources, including outbreak investigation, universal testing and testing at point of care.			true
	Monthly confirmed cases of influenza B Yamagata, all types of surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be of the Yamagata lineage of influenza B virus.	byamnotdefined	flu_monthly	LineChart	Confirmed cases	Monthly	Influenza B Yamagata	Undefined surveillance	-4043				Undefined surveillance may include sentinel or non-sentinel sites or both.			true
	Monthly confirmed cases of influenza B Yamagata, all types of surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be of the Yamagata lineage of influenza B virus.	byamcombined	flu_monthly	LineChart	Confirmed cases	Monthly	Influenza B Yamagata	All types of surveillance	-4043							true
	Monthly confirmed cases of influenza B Victoria, sentinel surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be of the Victoria lineage of influenza B virus.	bvicsentinel	flu_monthly	LineChart	Confirmed cases	Monthly	Influenza B Victoria	Sentinel surveillance	-4043				Sentinel sites collect data routinely from sites that are representative of the country's population.			true
	Monthly confirmed cases of influenza B Victoria, non-sentinel surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be of the Victoria lineage of influenza B virus.	bvicnonsentinel	flu_monthly	LineChart	Confirmed cases	Monthly	Influenza B Victoria	Non-sentinel surveillance	-4043				Non-sentinel sites include data from multiple sources, including outbreak investigation, universal testing and testing at point of care.			true
	Monthly confirmed cases of influenza B Victoria, undefined surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be of the Victoria lineage of influenza B virus.	bvicnotdefined	flu_monthly	LineChart	Confirmed cases	Monthly	Influenza B Victoria	Undefined surveillance	-4043				Undefined surveillance may include sentinel or non-sentinel sites or both.			true
	Monthly confirmed cases of influenza B Victoria, all types of surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be of the Victoria lineage of influenza B virus.	bviccombined	flu_monthly	LineChart	Confirmed cases	Monthly	Influenza B Victoria	All types of surveillance	-4043							true
	Monthly confirmed cases of influenza B (unknown subtype), sentinel surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be influenza B virus, but their lineage was not determined.	bnotdeterminedsentinel	flu_monthly	LineChart	Confirmed cases	Monthly	Influenza B unknown	Sentinel surveillance	-4043				Sentinel sites collect data routinely from sites that are representative of the country's population.			true
	Monthly confirmed cases of influenza B (unknown subtype), non-sentinel surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be influenza B virus, but their lineage was not determined.	bnotdeterminednonsentinel	flu_monthly	LineChart	Confirmed cases	Monthly	Influenza B unknown	Non-sentinel surveillance	-4043				Non-sentinel sites include data from multiple sources, including outbreak investigation, universal testing and testing at point of care.			true
	Monthly confirmed cases of influenza B (unknown subtype)	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be influenza B virus, but their lineage was not determined.	bnotdeterminednotdefined	flu_monthly	LineChart	Confirmed cases	Monthly	Influenza B unknown	Undefined surveillance	-4043				Undefined surveillance may include sentinel or non-sentinel sites or both.			true
	Monthly confirmed cases of influenza B (unknown subtype), all types of surveillance	Only a fraction of potential cases of influenza are tested by labs to confirm whether they have influenza and to identify their strain. The level of testing may vary between countries and over time. This shows the number of cases that were confirmed to be influenza B virus, but their lineage was not determined.	bnotdeterminedcombined	flu_monthly	LineChart	Confirmed cases	Monthly	Influenza B unknown	All types of surveillance	-4043							true
table	https://catalog.ourworldindata.org/explorers%2Fwho%2Flatest%2Fflu%2Fflu.csv	flu_weekly
columns	flu_weekly
	slug	name	type	tolerance	sourceName	additionalInfo	colorScaleNumericMinValue	color	colorScaleScheme	colorScaleNumericBins	unit	shortUnit
	country	Country	EntityName				0
	date	Day	Date				0
	reported_ari_cases	Cases of acute respiratory infections	Integer	30	FluID, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<li> FluID is a global human influenza surveillance dataset from the WHO that aggregates weekly data. Data comes from national influenza surveillance and regional networks such as EUROFlu.</li>\n<li> The WHO defines acute respiratory illnesses (ARIs) as sudden/acute onset of ≥1 of the following symptoms: cough, sore throat, shortness of breath, coryza, and were judged by a clinician to be due to an infection.</li>\n<li> The WHO defines influenza-like illnesses (ILIs) as acute respiratory infections with a fever ≥38ºC, a cough, and onset of symptoms within the last ten days. </li>\n<li> The WHO defines severe acute respiratory infections (SARIs) as acute respiratory infections with a history of fever or measured fever of ≥38 C°, cough, with onset within the last ten days, requiring hospitalization.</li>\n<li> Some countries use older definitions of these conditions. </li>\n<li> Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing. However, the FluID dataset does not list the data under these separate categories, so we show them together.</li>\n<li> You can find more detail on the surveillance strategies, sampling methods, and definitions used by each country here: https://apps.who.int/iris/bitstream/handle/10665/352183/WHO-EURO-2022-4760-44523-63025-eng.pdf?sequence=1&isAllowed=y </li>\n<b>Data preparation steps:</b>\n\n<li> We remove values where the number of SARI cases is below the number of inpatients - by definition SARI cases should also be inpatients so there should always be more inpatients than SARI cases. </li>\n<li> We remove values where the number of ILIs or ARIs per 1000 outpatients is ≥ 1000. </li>\n<li> We remove values where the number of SARIs per 100 inpatients is ≥ 100. </li>\n<li> We remove all values for the time-series of ILIs or ARIs per 1000 outpatients where all values are ≤ 1 or ≥ 999.</li>\n<li> We remove all values for the time-series of SARIs per 100 inpatients where all values are ≤ 1 or ≥ 99.</li>\n<li> We calculate regional aggregates by summing count variables.</li>\n<li> We calculate monthly variables from weekly variables - all weeks commencing in a particular month are aggregated to that month. </li>\n<li> We remove all values for years with less than 10 weekly data points.</li>\n<li> We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		reported cases
	reported_sari_cases	Cases of severe acute respiratory infections	Integer	30	FluID, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<li> FluID is a global human influenza surveillance dataset from the WHO that aggregates weekly data. Data comes from national influenza surveillance and regional networks such as EUROFlu.</li>\n<li> The WHO defines acute respiratory illnesses (ARIs) as sudden/acute onset of ≥1 of the following symptoms: cough, sore throat, shortness of breath, coryza, and were judged by a clinician to be due to an infection.</li>\n<li> The WHO defines influenza-like illnesses (ILIs) as acute respiratory infections with a fever ≥38ºC, a cough, and onset of symptoms within the last ten days. </li>\n<li> The WHO defines severe acute respiratory infections (SARIs) as acute respiratory infections with a history of fever or measured fever of ≥38 C°, cough, with onset within the last ten days, requiring hospitalization.</li>\n<li> Some countries use older definitions of these conditions. </li>\n<li> Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing. However, the FluID dataset does not list the data under these separate categories, so we show them together.</li>\n<li> You can find more detail on the surveillance strategies, sampling methods, and definitions used by each country here: https://apps.who.int/iris/bitstream/handle/10665/352183/WHO-EURO-2022-4760-44523-63025-eng.pdf?sequence=1&isAllowed=y </li>\n<b>Data preparation steps:</b>\n\n<li> We remove values where the number of SARI cases is below the number of inpatients - by definition SARI cases should also be inpatients so there should always be more inpatients than SARI cases. </li>\n<li> We remove values where the number of ILIs or ARIs per 1000 outpatients is ≥ 1000. </li>\n<li> We remove values where the number of SARIs per 100 inpatients is ≥ 100. </li>\n<li> We remove all values for the time-series of ILIs or ARIs per 1000 outpatients where all values are ≤ 1 or ≥ 999.</li>\n<li> We remove all values for the time-series of SARIs per 100 inpatients where all values are ≤ 1 or ≥ 99.</li>\n<li> We calculate regional aggregates by summing count variables.</li>\n<li> We calculate monthly variables from weekly variables - all weeks commencing in a particular month are aggregated to that month. </li>\n<li> We remove all values for years with less than 10 weekly data points.</li>\n<li> We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		reported cases
	reported_ili_cases	Cases of influenza-like illnesses	Integer	30	FluID, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<li> FluID is a global human influenza surveillance dataset from the WHO that aggregates weekly data. Data comes from national influenza surveillance and regional networks such as EUROFlu.</li>\n<li> The WHO defines acute respiratory illnesses (ARIs) as sudden/acute onset of ≥1 of the following symptoms: cough, sore throat, shortness of breath, coryza, and were judged by a clinician to be due to an infection.</li>\n<li> The WHO defines influenza-like illnesses (ILIs) as acute respiratory infections with a fever ≥38ºC, a cough, and onset of symptoms within the last ten days. </li>\n<li> The WHO defines severe acute respiratory infections (SARIs) as acute respiratory infections with a history of fever or measured fever of ≥38 C°, cough, with onset within the last ten days, requiring hospitalization.</li>\n<li> Some countries use older definitions of these conditions. </li>\n<li> Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing. However, the FluID dataset does not list the data under these separate categories, so we show them together.</li>\n<li> You can find more detail on the surveillance strategies, sampling methods, and definitions used by each country here: https://apps.who.int/iris/bitstream/handle/10665/352183/WHO-EURO-2022-4760-44523-63025-eng.pdf?sequence=1&isAllowed=y </li>\n<b>Data preparation steps:</b>\n\n<li> We remove values where the number of SARI cases is below the number of inpatients - by definition SARI cases should also be inpatients so there should always be more inpatients than SARI cases. </li>\n<li> We remove values where the number of ILIs or ARIs per 1000 outpatients is ≥ 1000. </li>\n<li> We remove values where the number of SARIs per 100 inpatients is ≥ 100. </li>\n<li> We remove all values for the time-series of ILIs or ARIs per 1000 outpatients where all values are ≤ 1 or ≥ 999.</li>\n<li> We remove all values for the time-series of SARIs per 100 inpatients where all values are ≤ 1 or ≥ 99.</li>\n<li> We calculate regional aggregates by summing count variables.</li>\n<li> We calculate monthly variables from weekly variables - all weeks commencing in a particular month are aggregated to that month. </li>\n<li> We remove all values for years with less than 10 weekly data points.</li>\n<li> We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		reported cases
	reported_sari_deaths	Reported deaths caused by severe acute respiratory infections	Integer	30	FluID, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<li> FluID is a global human influenza surveillance dataset from the WHO that aggregates weekly data. Data comes from national influenza surveillance and regional networks such as EUROFlu.</li>\n<li> The WHO defines acute respiratory illnesses (ARIs) as sudden/acute onset of ≥1 of the following symptoms: cough, sore throat, shortness of breath, coryza, and were judged by a clinician to be due to an infection.</li>\n<li> The WHO defines influenza-like illnesses (ILIs) as acute respiratory infections with a fever ≥38ºC, a cough, and onset of symptoms within the last ten days. </li>\n<li> The WHO defines severe acute respiratory infections (SARIs) as acute respiratory infections with a history of fever or measured fever of ≥38 C°, cough, with onset within the last ten days, requiring hospitalization.</li>\n<li> Some countries use older definitions of these conditions. </li>\n<li> Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing. However, the FluID dataset does not list the data under these separate categories, so we show them together.</li>\n<li> You can find more detail on the surveillance strategies, sampling methods, and definitions used by each country here: https://apps.who.int/iris/bitstream/handle/10665/352183/WHO-EURO-2022-4760-44523-63025-eng.pdf?sequence=1&isAllowed=y </li>\n<b>Data preparation steps:</b>\n\n<li> We remove values where the number of SARI cases is below the number of inpatients - by definition SARI cases should also be inpatients so there should always be more inpatients than SARI cases. </li>\n<li> We remove values where the number of ILIs or ARIs per 1000 outpatients is ≥ 1000. </li>\n<li> We remove values where the number of SARIs per 100 inpatients is ≥ 100. </li>\n<li> We remove all values for the time-series of ILIs or ARIs per 1000 outpatients where all values are ≤ 1 or ≥ 999.</li>\n<li> We remove all values for the time-series of SARIs per 100 inpatients where all values are ≤ 1 or ≥ 99.</li>\n<li> We calculate regional aggregates by summing count variables.</li>\n<li> We calculate monthly variables from weekly variables - all weeks commencing in a particular month are aggregated to that month. </li>\n<li> We remove all values for years with less than 10 weekly data points.</li>\n<li> We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		reported deaths
	ili_cases_per_thousand_outpatients	Cases of influenza-like illness per thousand outpatients	Numeric	30	FluID, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<li> FluID is a global human influenza surveillance dataset from the WHO that aggregates weekly data. Data comes from national influenza surveillance and regional networks such as EUROFlu.</li>\n<li> The WHO defines acute respiratory illnesses (ARIs) as sudden/acute onset of ≥1 of the following symptoms: cough, sore throat, shortness of breath, coryza, and were judged by a clinician to be due to an infection.</li>\n<li> The WHO defines influenza-like illnesses (ILIs) as acute respiratory infections with a fever ≥38ºC, a cough, and onset of symptoms within the last ten days. </li>\n<li> The WHO defines severe acute respiratory infections (SARIs) as acute respiratory infections with a history of fever or measured fever of ≥38 C°, cough, with onset within the last ten days, requiring hospitalization.</li>\n<li> Some countries use older definitions of these conditions. </li>\n<li> Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing. However, the FluID dataset does not list the data under these separate categories, so we show them together.</li>\n<li> You can find more detail on the surveillance strategies, sampling methods, and definitions used by each country here: https://apps.who.int/iris/bitstream/handle/10665/352183/WHO-EURO-2022-4760-44523-63025-eng.pdf?sequence=1&isAllowed=y </li>\n<b>Data preparation steps:</b>\n\n<li> We remove values where the number of SARI cases is below the number of inpatients - by definition SARI cases should also be inpatients so there should always be more inpatients than SARI cases. </li>\n<li> We remove values where the number of ILIs or ARIs per 1000 outpatients is ≥ 1000. </li>\n<li> We remove values where the number of SARIs per 100 inpatients is ≥ 100. </li>\n<li> We remove all values for the time-series of ILIs or ARIs per 1000 outpatients where all values are ≤ 1 or ≥ 999.</li>\n<li> We remove all values for the time-series of SARIs per 100 inpatients where all values are ≤ 1 or ≥ 99.</li>\n<li> We calculate regional aggregates by summing count variables.</li>\n<li> We calculate monthly variables from weekly variables - all weeks commencing in a particular month are aggregated to that month. </li>\n<li> We remove all values for years with less than 10 weekly data points.</li>\n<li> We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		reported cases per 1,000 outpatients
	sari_cases_per_hundred_inpatients	Cases of severe acute respiratory illness per thousand outpatients	Numeric	30	FluID, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<li> FluID is a global human influenza surveillance dataset from the WHO that aggregates weekly data. Data comes from national influenza surveillance and regional networks such as EUROFlu.</li>\n<li> The WHO defines acute respiratory illnesses (ARIs) as sudden/acute onset of ≥1 of the following symptoms: cough, sore throat, shortness of breath, coryza, and were judged by a clinician to be due to an infection.</li>\n<li> The WHO defines influenza-like illnesses (ILIs) as acute respiratory infections with a fever ≥38ºC, a cough, and onset of symptoms within the last ten days. </li>\n<li> The WHO defines severe acute respiratory infections (SARIs) as acute respiratory infections with a history of fever or measured fever of ≥38 C°, cough, with onset within the last ten days, requiring hospitalization.</li>\n<li> Some countries use older definitions of these conditions. </li>\n<li> Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing. However, the FluID dataset does not list the data under these separate categories, so we show them together.</li>\n<li> You can find more detail on the surveillance strategies, sampling methods, and definitions used by each country here: https://apps.who.int/iris/bitstream/handle/10665/352183/WHO-EURO-2022-4760-44523-63025-eng.pdf?sequence=1&isAllowed=y </li>\n<b>Data preparation steps:</b>\n\n<li> We remove values where the number of SARI cases is below the number of inpatients - by definition SARI cases should also be inpatients so there should always be more inpatients than SARI cases. </li>\n<li> We remove values where the number of ILIs or ARIs per 1000 outpatients is ≥ 1000. </li>\n<li> We remove values where the number of SARIs per 100 inpatients is ≥ 100. </li>\n<li> We remove all values for the time-series of ILIs or ARIs per 1000 outpatients where all values are ≤ 1 or ≥ 999.</li>\n<li> We remove all values for the time-series of SARIs per 100 inpatients where all values are ≤ 1 or ≥ 99.</li>\n<li> We calculate regional aggregates by summing count variables.</li>\n<li> We calculate monthly variables from weekly variables - all weeks commencing in a particular month are aggregated to that month. </li>\n<li> We remove all values for years with less than 10 weekly data points.</li>\n<li> We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		reported cases per 100 inpatients
	ah1n12009sentinel	A H1N12009 - Sentinel surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	ah1n12009nonsentinel	A H1N12009 - Non-sentinel surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	ah1n12009notdefined	A H1N12009 - Undefined surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	ah1n12009combined	A H1N12009 - All types of surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	ah1sentinel	A H1 - Sentinel surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	ah1nonsentinel	A H1 - Non-sentinel surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	ah1notdefined	A H1 - Undefined surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	ah1combined	A H1 - All types of surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	ah3sentinel	A H3 - Sentinel surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	ah3nonsentinel	A H3 - Non-sentinel surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	ah3notdefined	A H3 - Undefined surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	ah3combined	A H3 - All types of surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	ah5sentinel	A H5 - Sentinel surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	ah5nonsentinel	A H5 - Non-sentinel surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	ah5notdefined	A H5 - Undefined surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	ah5combined	A H5 - All types of surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	ah7n9sentinel	A H7N9 - Sentinel surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	ah7n9nonsentinel	A H7N9 - Non-sentinel surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	ah7n9notdefined	A H7N9 - Undefined surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	ah7n9combined	A H7N9 - All types of surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	a_no_subtypesentinel	A Unknown - Sentinel surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	a_no_subtypenonsentinel	A Unknown - Non-sentinel surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	a_no_subtypenotdefined	A Unknown - Undefined surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	a_no_subtypecombined	A Unknown - All types of surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	inf_asentinel	Influenza A - Sentinel surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	inf_anonsentinel	Influenza A - Non-sentinel surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	inf_anotdefined	Influenza A - Undefined surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	inf_acombined	Influenza A - All types of surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	byamsentinel	B Yamagata - Sentinel surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	byamnonsentinel	B Yamagata - Non-sentinel surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	byamnotdefined	B Yamagata - Undefined surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	byamcombined	B Yamagata - All types of surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	bvicsentinel	B Victoria - Sentinel surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	bvicnonsentinel	B Victoria - Non-sentinel surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	bvicnotdefined	B Victoria - Undefined surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	bviccombined	B Victoria - All types of surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	bnotdeterminedsentinel	B Unknown - Sentinel surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	bnotdeterminednonsentinel	B Unknown - Non-sentinel surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	bnotdeterminednotdefined	B Unknown - Undefined surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	bnotdeterminedcombined	B Unknown - All types of surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	inf_bsentinel	Influenza B - Sentinel surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	inf_bnonsentinel	Influenza B - Non-sentinel surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	inf_bnotdefined	Influenza B - Undefined surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	inf_bcombined	Influenza B - All types of surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	inf_allsentinel	All strains - Sentinel surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	inf_allnonsentinel	All strains - Non-sentinel surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	inf_allnotdefined	All strains - Undefined surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	inf_allcombined	All strains - All types of surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd	10;50;100;500;1000;5000;10000	confirmed cases
	pcnt_possentinel	Share of positive tests - Sentinel surveillance	Percentage	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd	10;20;30;40;50	%	%
	pcnt_posnonsentinel	Share of positive tests - Non-sentinel surveillance	Percentage	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd	10;20;30;40;50	%	%
	pcnt_posnotdefined	Share of positive tests - Undefined surveillance	Percentage	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd	10;20;30;40;50	%	%
	pcnt_poscombined	Share of positive tests - All types of surveillance	Percentage	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd	10;20;30;40;50	%	%
	ah1n12009combined_zfilled	A H1N12009	Integer	0	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0	#8C2D04			confirmed cases
	ah1combined_zfilled	A H1	Integer	0	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0	#CC4C02			confirmed cases
	ah3combined_zfilled	A H3	Integer	0	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0	#EC7014			confirmed cases
	ah5combined_zfilled	A H5	Integer	0	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0	#FE9929			confirmed cases
	ah7n9combined_zfilled	A H7N9	Integer	0	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0	#FEC44F			confirmed cases
	a_no_subtypecombined_zfilled	A Unknown	Integer	0	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0	#FEE391			confirmed cases
	inf_acombined_zfilled	All Influenza A	Integer	0	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	bviccombined_zfilled	B Victoria	Integer	0	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0	#02818A			confirmed cases
	byamcombined_zfilled	B Yamagata	Integer	0	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0	#67A9CF			confirmed cases
	bnotdeterminedcombined_zfilled	B Unknown	Integer	0	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0	#BDC9E1			confirmed cases
	inf_bcombined_zfilled	All Influenza B	Integer	0	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	ah1n12009sentinel_zfilled	A H1N12009	Integer	0	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>		#8C2D04			confirmed cases
	ah1sentinel_zfilled	A H1	Integer	0	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>		#CC4C02			confirmed cases
	ah3sentinel_zfilled	A H3	Integer	0	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>		#EC7014			confirmed cases
	ah5sentinel_zfilled	A H5	Integer	0	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>		#FE9929			confirmed cases
	ah7n9sentinel_zfilled	A H7N9	Integer	0	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>		#FEC44F			confirmed cases
	a_no_subtypesentinel_zfilled	A Unknown	Integer	0	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>		#FEE391			confirmed cases
	inf_asentinel_zfilled	All Influenza A	Integer	0	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	bvicsentinel_zfilled	B Victoria	Integer	0	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>		#02818A			confirmed cases
	byamsentinel_zfilled	B Yamagata	Integer	0	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>		#67A9CF			confirmed cases
	bnotdeterminedsentinel_zfilled	B Unknown	Integer	0	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>		#BDC9E1			confirmed cases
	inf_bsentinel_zfilled	All Influenza B	Integer	0	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	ah1n12009nonsentinel_zfilled	A H1N12009	Integer	0	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>		#8C2D04			confirmed cases
	ah1nonsentinel_zfilled	A H1	Integer	0	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>		#CC4C02			confirmed cases
	ah3nonsentinel_zfilled	A H3	Integer	0	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>		#EC7014			confirmed cases
	ah5nonsentinel_zfilled	A H5	Integer	0	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>		#FE9929			confirmed cases
	ah7n9nonsentinel_zfilled	A H7N9	Integer	0	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>		#FEC44F			confirmed cases
	a_no_subtypenonsentinel_zfilled	A Unknown	Integer	0	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>		#FEE391			confirmed cases
	inf_anonsentinel_zfilled	All Influenza A	Integer	0	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	bvicnonsentinel_zfilled	B Victoria	Integer	0	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>		#02818A			confirmed cases
	byamnonsentinel_zfilled	B Yamagata	Integer	0	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>		#67A9CF			confirmed cases
	bnotdeterminednonsentinel_zfilled	B Unknown	Integer	0	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>		#BDC9E1			confirmed cases
	inf_bnonsentinel_zfilled	All Influenza B	Integer	0	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	ah1n12009notdefined_zfilled	A H1N12009	Integer	0	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>		#8C2D04			confirmed cases
	ah1notdefined_zfilled	A H1	Integer	0	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>		#CC4C02			confirmed cases
	ah3notdefined_zfilled	A H3	Integer	0	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>		#EC7014			confirmed cases
	ah5notdefined_zfilled	A H5	Integer	0	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>		#FE9929			confirmed cases
	ah7n9notdefined_zfilled	A H7N9	Integer	0	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>		#FEC44F			confirmed cases
	a_no_subtypenotdefined_zfilled	A Unknown	Integer	0	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>		#FEE391			confirmed cases
	inf_anotdefined_zfilled	All Influenza A	Integer	0	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0				confirmed cases
	bvicnotdefined_zfilled	B Victoria	Integer	0	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>		#02818A			confirmed cases
	byamnotdefined_zfilled	B Yamagata	Integer	0	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>		#67A9CF			confirmed cases
	bnotdeterminednotdefined_zfilled	B Unknown	Integer	0	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>		#BDC9E1			confirmed cases
	inf_bnotdefined_zfilled	All Influenza B	Integer	0	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza A strains do not sum to the total value given for influenza A\n&nbsp;&nbsp;&nbsp;&nbsp;- Where all the influenza B strains do not sum to the total value given for influenza B\n&nbsp;&nbsp;&nbsp;&nbsp;- Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n&nbsp;&nbsp;&nbsp;&nbsp;- Number of negative influenza tests + number of positive tests\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens processed\n&nbsp;&nbsp;&nbsp;&nbsp;- Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n&nbsp;&nbsp;&nbsp;&nbsp;- For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0				confirmed cases
table	https://catalog.ourworldindata.org/explorers%2Fwho%2Flatest%2Fflu%2Fflu_monthly.csv	flu_monthly
columns	flu_monthly
	slug	name	type	tolerance	sourceName	additionalInfo	colorScaleNumericMinValue	color	colorScaleScheme	colorScaleNumericBins	unit	shortUnit
	country	Country	EntityName				0
	month_date	Month	Date				0
	reported_ari_cases	Cases of acute respiratory infections	Integer	30	FluID, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<li> FluID is a global human influenza surveillance dataset from the WHO that aggregates weekly data. Data comes from national influenza surveillance and regional networks such as EUROFlu.</li>\n<li> The WHO defines acute respiratory illnesses (ARIs) as sudden/acute onset of ≥1 of the following symptoms: cough, sore throat, shortness of breath, coryza, and were judged by a clinician to be due to an infection.</li>\n<li> The WHO defines influenza-like illnesses (ILIs) as acute respiratory infections with a fever ≥38ºC, a cough, and onset of symptoms within the last ten days. </li>\n<li> The WHO defines severe acute respiratory infections (SARIs) as acute respiratory infections with a history of fever or measured fever of ≥38 C°, cough, with onset within the last ten days, requiring hospitalization.</li>\n<li> Some countries use older definitions of these conditions. </li>\n<li> Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing. However, the FluID dataset does not list the data under these separate categories, so we show them together.</li>\n<li> You can find more detail on the surveillance strategies, sampling methods, and definitions used by each country here: https://apps.who.int/iris/bitstream/handle/10665/352183/WHO-EURO-2022-4760-44523-63025-eng.pdf?sequence=1&isAllowed=y </li>\n<b>Data preparation steps:</b>\n\n<li> We remove values where the number of SARI cases is below the number of inpatients - by definition SARI cases should also be inpatients so there should always be more inpatients than SARI cases. </li>\n<li> We remove values where the number of ILIs or ARIs per 1000 outpatients is ≥ 1000. </li>\n<li> We remove values where the number of SARIs per 100 inpatients is ≥ 100. </li>\n<li> We remove all values for the time-series of ILIs or ARIs per 1000 outpatients where all values are ≤ 1 or ≥ 999.</li>\n<li> We remove all values for the time-series of SARIs per 100 inpatients where all values are ≤ 1 or ≥ 99.</li>\n<li> We calculate regional aggregates by summing count variables.</li>\n<li> We calculate monthly variables from weekly variables - all weeks commencing in a particular month are aggregated to that month. </li>\n<li> We remove all values for years with less than 10 weekly data points.</li>\n<li> We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		reported cases
	reported_sari_cases	Cases of severe acute respiratory infections	Integer	30	FluID, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<li> FluID is a global human influenza surveillance dataset from the WHO that aggregates weekly data. Data comes from national influenza surveillance and regional networks such as EUROFlu.</li>\n<li> The WHO defines acute respiratory illnesses (ARIs) as sudden/acute onset of ≥1 of the following symptoms: cough, sore throat, shortness of breath, coryza, and were judged by a clinician to be due to an infection.</li>\n<li> The WHO defines influenza-like illnesses (ILIs) as acute respiratory infections with a fever ≥38ºC, a cough, and onset of symptoms within the last ten days. </li>\n<li> The WHO defines severe acute respiratory infections (SARIs) as acute respiratory infections with a history of fever or measured fever of ≥38 C°, cough, with onset within the last ten days, requiring hospitalization.</li>\n<li> Some countries use older definitions of these conditions. </li>\n<li> Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing. However, the FluID dataset does not list the data under these separate categories, so we show them together.</li>\n<li> You can find more detail on the surveillance strategies, sampling methods, and definitions used by each country here: https://apps.who.int/iris/bitstream/handle/10665/352183/WHO-EURO-2022-4760-44523-63025-eng.pdf?sequence=1&isAllowed=y </li>\n<b>Data preparation steps:</b>\n\n<li> We remove values where the number of SARI cases is below the number of inpatients - by definition SARI cases should also be inpatients so there should always be more inpatients than SARI cases. </li>\n<li> We remove values where the number of ILIs or ARIs per 1000 outpatients is ≥ 1000. </li>\n<li> We remove values where the number of SARIs per 100 inpatients is ≥ 100. </li>\n<li> We remove all values for the time-series of ILIs or ARIs per 1000 outpatients where all values are ≤ 1 or ≥ 999.</li>\n<li> We remove all values for the time-series of SARIs per 100 inpatients where all values are ≤ 1 or ≥ 99.</li>\n<li> We calculate regional aggregates by summing count variables.</li>\n<li> We calculate monthly variables from weekly variables - all weeks commencing in a particular month are aggregated to that month. </li>\n<li> We remove all values for years with less than 10 weekly data points.</li>\n<li> We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		reported cases
	reported_ili_cases	Cases of influenza-like illnesses	Integer	30	FluID, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<li> FluID is a global human influenza surveillance dataset from the WHO that aggregates weekly data. Data comes from national influenza surveillance and regional networks such as EUROFlu.</li>\n<li> The WHO defines acute respiratory illnesses (ARIs) as sudden/acute onset of ≥1 of the following symptoms: cough, sore throat, shortness of breath, coryza, and were judged by a clinician to be due to an infection.</li>\n<li> The WHO defines influenza-like illnesses (ILIs) as acute respiratory infections with a fever ≥38ºC, a cough, and onset of symptoms within the last ten days. </li>\n<li> The WHO defines severe acute respiratory infections (SARIs) as acute respiratory infections with a history of fever or measured fever of ≥38 C°, cough, with onset within the last ten days, requiring hospitalization.</li>\n<li> Some countries use older definitions of these conditions. </li>\n<li> Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing. However, the FluID dataset does not list the data under these separate categories, so we show them together.</li>\n<li> You can find more detail on the surveillance strategies, sampling methods, and definitions used by each country here: https://apps.who.int/iris/bitstream/handle/10665/352183/WHO-EURO-2022-4760-44523-63025-eng.pdf?sequence=1&isAllowed=y </li>\n<b>Data preparation steps:</b>\n\n<li> We remove values where the number of SARI cases is below the number of inpatients - by definition SARI cases should also be inpatients so there should always be more inpatients than SARI cases. </li>\n<li> We remove values where the number of ILIs or ARIs per 1000 outpatients is ≥ 1000. </li>\n<li> We remove values where the number of SARIs per 100 inpatients is ≥ 100. </li>\n<li> We remove all values for the time-series of ILIs or ARIs per 1000 outpatients where all values are ≤ 1 or ≥ 999.</li>\n<li> We remove all values for the time-series of SARIs per 100 inpatients where all values are ≤ 1 or ≥ 99.</li>\n<li> We calculate regional aggregates by summing count variables.</li>\n<li> We calculate monthly variables from weekly variables - all weeks commencing in a particular month are aggregated to that month. </li>\n<li> We remove all values for years with less than 10 weekly data points.</li>\n<li> We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		reported cases
	reported_sari_deaths	Reported deaths caused by severe acute respiratory infections	Integer	30	FluID, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<li> FluID is a global human influenza surveillance dataset from the WHO that aggregates weekly data. Data comes from national influenza surveillance and regional networks such as EUROFlu.</li>\n<li> The WHO defines acute respiratory illnesses (ARIs) as sudden/acute onset of ≥1 of the following symptoms: cough, sore throat, shortness of breath, coryza, and were judged by a clinician to be due to an infection.</li>\n<li> The WHO defines influenza-like illnesses (ILIs) as acute respiratory infections with a fever ≥38ºC, a cough, and onset of symptoms within the last ten days. </li>\n<li> The WHO defines severe acute respiratory infections (SARIs) as acute respiratory infections with a history of fever or measured fever of ≥38 C°, cough, with onset within the last ten days, requiring hospitalization.</li>\n<li> Some countries use older definitions of these conditions. </li>\n<li> Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing. However, the FluID dataset does not list the data under these separate categories, so we show them together.</li>\n<li> You can find more detail on the surveillance strategies, sampling methods, and definitions used by each country here: https://apps.who.int/iris/bitstream/handle/10665/352183/WHO-EURO-2022-4760-44523-63025-eng.pdf?sequence=1&isAllowed=y </li>\n<b>Data preparation steps:</b>\n\n<li> We remove values where the number of SARI cases is below the number of inpatients - by definition SARI cases should also be inpatients so there should always be more inpatients than SARI cases. </li>\n<li> We remove values where the number of ILIs or ARIs per 1000 outpatients is ≥ 1000. </li>\n<li> We remove values where the number of SARIs per 100 inpatients is ≥ 100. </li>\n<li> We remove all values for the time-series of ILIs or ARIs per 1000 outpatients where all values are ≤ 1 or ≥ 999.</li>\n<li> We remove all values for the time-series of SARIs per 100 inpatients where all values are ≤ 1 or ≥ 99.</li>\n<li> We calculate regional aggregates by summing count variables.</li>\n<li> We calculate monthly variables from weekly variables - all weeks commencing in a particular month are aggregated to that month. </li>\n<li> We remove all values for years with less than 10 weekly data points.</li>\n<li> We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		reported deaths
	ili_cases_per_thousand_outpatients	Cases of influenza-like illness per thousand outpatients	Numeric	30	FluID, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<li> FluID is a global human influenza surveillance dataset from the WHO that aggregates weekly data. Data comes from national influenza surveillance and regional networks such as EUROFlu.</li>\n<li> The WHO defines acute respiratory illnesses (ARIs) as sudden/acute onset of ≥1 of the following symptoms: cough, sore throat, shortness of breath, coryza, and were judged by a clinician to be due to an infection.</li>\n<li> The WHO defines influenza-like illnesses (ILIs) as acute respiratory infections with a fever ≥38ºC, a cough, and onset of symptoms within the last ten days. </li>\n<li> The WHO defines severe acute respiratory infections (SARIs) as acute respiratory infections with a history of fever or measured fever of ≥38 C°, cough, with onset within the last ten days, requiring hospitalization.</li>\n<li> Some countries use older definitions of these conditions. </li>\n<li> Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing. However, the FluID dataset does not list the data under these separate categories, so we show them together.</li>\n<li> You can find more detail on the surveillance strategies, sampling methods, and definitions used by each country here: https://apps.who.int/iris/bitstream/handle/10665/352183/WHO-EURO-2022-4760-44523-63025-eng.pdf?sequence=1&isAllowed=y </li>\n<b>Data preparation steps:</b>\n\n<li> We remove values where the number of SARI cases is below the number of inpatients - by definition SARI cases should also be inpatients so there should always be more inpatients than SARI cases. </li>\n<li> We remove values where the number of ILIs or ARIs per 1000 outpatients is ≥ 1000. </li>\n<li> We remove values where the number of SARIs per 100 inpatients is ≥ 100. </li>\n<li> We remove all values for the time-series of ILIs or ARIs per 1000 outpatients where all values are ≤ 1 or ≥ 999.</li>\n<li> We remove all values for the time-series of SARIs per 100 inpatients where all values are ≤ 1 or ≥ 99.</li>\n<li> We calculate regional aggregates by summing count variables.</li>\n<li> We calculate monthly variables from weekly variables - all weeks commencing in a particular month are aggregated to that month. </li>\n<li> We remove all values for years with less than 10 weekly data points.</li>\n<li> We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		reported cases per 1,000 outpatients
	sari_cases_per_hundred_inpatients	Cases of severe acute respiratory illness per thousand outpatients	Numeric	30	FluID, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<li> FluID is a global human influenza surveillance dataset from the WHO that aggregates weekly data. Data comes from national influenza surveillance and regional networks such as EUROFlu.</li>\n<li> The WHO defines acute respiratory illnesses (ARIs) as sudden/acute onset of ≥1 of the following symptoms: cough, sore throat, shortness of breath, coryza, and were judged by a clinician to be due to an infection.</li>\n<li> The WHO defines influenza-like illnesses (ILIs) as acute respiratory infections with a fever ≥38ºC, a cough, and onset of symptoms within the last ten days. </li>\n<li> The WHO defines severe acute respiratory infections (SARIs) as acute respiratory infections with a history of fever or measured fever of ≥38 C°, cough, with onset within the last ten days, requiring hospitalization.</li>\n<li> Some countries use older definitions of these conditions. </li>\n<li> Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing. However, the FluID dataset does not list the data under these separate categories, so we show them together.</li>\n<li> You can find more detail on the surveillance strategies, sampling methods, and definitions used by each country here: https://apps.who.int/iris/bitstream/handle/10665/352183/WHO-EURO-2022-4760-44523-63025-eng.pdf?sequence=1&isAllowed=y </li>\n<b>Data preparation steps:</b>\n\n<li> We remove values where the number of SARI cases is below the number of inpatients - by definition SARI cases should also be inpatients so there should always be more inpatients than SARI cases. </li>\n<li> We remove values where the number of ILIs or ARIs per 1000 outpatients is ≥ 1000. </li>\n<li> We remove values where the number of SARIs per 100 inpatients is ≥ 100. </li>\n<li> We remove all values for the time-series of ILIs or ARIs per 1000 outpatients where all values are ≤ 1 or ≥ 999.</li>\n<li> We remove all values for the time-series of SARIs per 100 inpatients where all values are ≤ 1 or ≥ 99.</li>\n<li> We calculate regional aggregates by summing count variables.</li>\n<li> We calculate monthly variables from weekly variables - all weeks commencing in a particular month are aggregated to that month. </li>\n<li> We remove all values for years with less than 10 weekly data points.</li>\n<li> We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		reported cases per 100 inpatients
	ah1n12009sentinel	A H1N12009 - Sentinel surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	ah1n12009nonsentinel	A H1N12009 - Non-sentinel surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	ah1n12009notdefined	A H1N12009 - Undefined surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	ah1n12009combined	A H1N12009 - All types of surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	ah1sentinel	A H1 - Sentinel surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	ah1nonsentinel	A H1 - Non-sentinel surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	ah1notdefined	A H1 - Undefined surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	ah1combined	A H1 - All types of surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	ah3sentinel	Sentinel surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	ah3nonsentinel	Non-sentinel surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	ah3notdefined	Undefined surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	ah3combined	All types of surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	ah5sentinel	Sentinel surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	ah5nonsentinel	Non-sentinel surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	ah5notdefined	Undefined surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	ah5combined	All types of surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	ah7n9sentinel	Sentinel surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	ah7n9nonsentinel	Non-sentinel surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	ah7n9notdefined	Undefined surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	ah7n9combined	All types of surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	a_no_subtypesentinel	Sentinel surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	a_no_subtypenonsentinel	Non-sentinel surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	a_no_subtypenotdefined	Undefined surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	a_no_subtypecombined	All types of surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	inf_asentinel	Sentinel surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	inf_anonsentinel	Non-sentinel surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	inf_anotdefined	Undefined surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	inf_acombined	All types of surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	byamsentinel	Sentinel surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	byamnonsentinel	Non-sentinel surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	byamnotdefined	Undefined surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	byamcombined	All types of surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	bvicsentinel	Sentinel surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	bvicnonsentinel	Non-sentinel surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	bvicnotdefined	Undefined surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	bviccombined	All types of surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	bnotdeterminedsentinel	Sentinel surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	bnotdeterminednonsentinel	Non-sentinel surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	bnotdeterminednotdefined	Undefined surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	bnotdeterminedcombined	All types of surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	inf_bsentinel	Sentinel surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	inf_bnonsentinel	Non-sentinel surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	inf_bnotdefined	Undefined surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	inf_bcombined	All types of surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	inf_allsentinel	Sentinel surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	inf_allnonsentinel	Non-sentinel surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	inf_allnotdefined	Undefined surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	inf_allcombined	All types of surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	inf_negativesentinel	Sentinel surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd
	inf_negativenonsentinel	Non-sentinel surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd
	inf_negativenotdefined	Undefined surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd
	inf_negativecombined	All types of surveillance	Integer	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd
	pcnt_possentinel	Sentinel surveillance	Percentage	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd	10;20;30;40;50	%	%
	pcnt_posnonsentinel	Non-sentinel surveillance	Percentage	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd	10;20;30;40;50	%	%
	pcnt_posnotdefined	Undefined surveillance	Percentage	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd	10;20;30;40;50	%	%
	pcnt_poscombined	All types of surveillance	Percentage	30	FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd	10;20;30;40;50	%	%
	ah1n12009combined_zfilled	A H1N12009	Integer		FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0	#8C2D04			confirmed cases
	ah1combined_zfilled	A H1	Integer		FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0	#CC4C02			confirmed cases
	ah3combined_zfilled	A H3	Integer		FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0	#EC7014			confirmed cases
	ah5combined_zfilled	A H5	Integer		FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0	#FE9929			confirmed cases
	ah7n9combined_zfilled	A H7N9	Integer		FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0	#FEC44F			confirmed cases
	a_no_subtypecombined_zfilled	A Unknown	Integer		FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0	#FEE391			confirmed cases
	inf_acombined_zfilled	All Influenza A	Integer		FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	bviccombined_zfilled	B Victoria	Integer		FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0	#02818A			confirmed cases
	byamcombined_zfilled	B Yamagata	Integer		FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0	#67A9CF			confirmed cases
	bnotdeterminedcombined_zfilled	B Unknown	Integer		FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0	#BDC9E1			confirmed cases
	inf_bcombined_zfilled	All Influenza B	Integer		FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	ah1n12009sentinel_zfilled	A H1N12009	Integer		FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>		#8C2D04			confirmed cases
	ah1sentinel_zfilled	A H1	Integer		FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>		#CC4C02			confirmed cases
	ah3sentinel_zfilled	A H3	Integer		FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>		#EC7014			confirmed cases
	ah5sentinel_zfilled	A H5	Integer		FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>		#FE9929			confirmed cases
	ah7n9sentinel_zfilled	A H7N9	Integer		FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>		#FEC44F			confirmed cases
	a_no_subtypesentinel_zfilled	A Unknown	Integer		FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>		#FEE391			confirmed cases
	inf_asentinel_zfilled	All Influenza A	Integer		FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	bvicsentinel_zfilled	B Victoria	Integer		FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>		#02818A			confirmed cases
	byamsentinel_zfilled	B Yamagata	Integer		FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>		#67A9CF			confirmed cases
	bnotdeterminedsentinel_zfilled	B Unknown	Integer		FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>		#BDC9E1			confirmed cases
	inf_bsentinel_zfilled	All Influenza B	Integer		FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	ah1n12009nonsentinel_zfilled	A H1N12009	Integer		FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>		#8C2D04			confirmed cases
	ah1nonsentinel_zfilled	A H1	Integer		FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>		#CC4C02			confirmed cases
	ah3nonsentinel_zfilled	A H3	Integer		FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>		#EC7014			confirmed cases
	ah5nonsentinel_zfilled	A H5	Integer		FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>		#FE9929			confirmed cases
	ah7n9nonsentinel_zfilled	A H7N9	Integer		FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>		#FEC44F			confirmed cases
	a_no_subtypenonsentinel_zfilled	A Unknown	Integer		FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>		#FEE391			confirmed cases
	inf_anonsentinel_zfilled	All Influenza A	Integer		FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	bvicnonsentinel_zfilled	B Victoria	Integer		FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>		#02818A			confirmed cases
	byamnonsentinel_zfilled	B Yamagata	Integer		FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>		#67A9CF			confirmed cases
	bnotdeterminednonsentinel_zfilled	B Unknown	Integer		FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>		#BDC9E1			confirmed cases
	inf_bnonsentinel_zfilled	All Influenza B	Integer		FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	ah1n12009notdefined_zfilled	A H1N12009	Integer		FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>		#8C2D04			confirmed cases
	ah1notdefined_zfilled	A H1	Integer		FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>		#CC4C02			confirmed cases
	ah3notdefined_zfilled	A H3	Integer		FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>		#EC7014			confirmed cases
	ah5notdefined_zfilled	A H5	Integer		FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>		#FE9929			confirmed cases
	ah7n9notdefined_zfilled	A H7N9	Integer		FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>		#FEC44F			confirmed cases
	a_no_subtypenotdefined_zfilled	A Unknown	Integer		FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>		#FEE391			confirmed cases
	inf_anotdefined_zfilled	All Influenza A	Integer		FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases
	bvicnotdefined_zfilled	B Victoria	Integer		FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>		#02818A			confirmed cases
	byamnotdefined_zfilled	B Yamagata	Integer		FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>		#67A9CF			confirmed cases
	bnotdeterminednotdefined_zfilled	B Unknown	Integer		FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>		#BDC9E1			confirmed cases
	inf_bnotdefined_zfilled	All Influenza B	Integer		FluNet, World Health Organization (2023)	<b>Dataset Description:</b><br/> \n<ul>\n<li> This is a human influenza surveillance dataset that aggregates data from (1) the Global Influenza Surveillance and Response System (GISRS), (2) other national influenza reference laboratories that collaborate with the GISRS, and (3) other influenza surveillance data uploaded from WHO regional databases.</li>\n<li>Some of these samples are tested to determine whether they are influenza and whether they are influenza A or influenza B. Some surveillance centers also test the samples to identify their subtype. These are described as strains for influenza A (e.g., A H7N9) and lineages for influenza B (e.g., B Yamagata). This testing can use molecular detection, virus culture, or immunological methods.</li>\n<li>  Surveillance data from each country may come from sentinel sites, non-sentinel sites, or universal testing.</li>\n<li>  According to the WHO, a sentinel surveillance system comprises one or more selected healthcare facilities or providers that routinely and consistently collect data from patients who meet the criteria for an illness. Sentinel sites are often selected from different geographical locations to represent the country's population. These sites collect representative clinical specimens from all or a subset of patients according to a randomized / systematic / convenience sampling protocol. Sentinel surveillance systems provide an efficient way to obtain high-quality data on relatively common conditions from a manageable number of locations.</li>\n<li>  A non-sentinel surveillance system includes other systems (e.g., laboratory surveillance). In the WHO European Region, they perform surveillance for viruses from clinical diagnostic laboratories, outbreaks, or universal ARI surveillance systems that do not have randomized / standardized sampling strategies.</li>\n<li>  Some samples are not categorized as either sentinel or non-sentinel surveillance. We show these as ‘undefined’.</li>\n\n<b>Data preparation steps:</b>\n\n<li>  Remove rows where confirmed cases by influenza strain do not sum as expected. Specifically:\n    - Where all the influenza A strains do not sum to the total value given for influenza A\n    - Where all the influenza B strains do not sum to the total value given for influenza B\n    - Where influenza A + influenza B does not equal total influenza confirmed cases\n</li>\n<li> We follow the WHO’s method to calculate the ‘Share of tests that test positive (%).’ They suggest using three possible denominators, in order of preference: \n    - Number of negative influenza tests + number of positive tests\n    - Number of specimens processed\n    - Number of specimens received</li>\n<li>  We follow the above approach at the country level. At the regional level, we do not consider the number of negative influenza tests as, historically, there is not much data available for this variable. <br/>\n    - For example, there are many weeks where only one country has a value for negative influenza tests. Instead, we use specimens processed as the primary denominator as data for this is much more plentiful.\n</li>\n<li>  We set the negative tests to NA where the sum of negative tests is 0, and the sum of the negative and positive tests does not equal the number of processed tests.</li>\n<li>  We calculate an aggregate for the UK by summing data for England, N.Ireland, Scotland, and Wales. </li>\n<li>  We calculate global and hemisphere aggregates by summing count variables and averaging rate variables.</li>\n<li>  We calculate monthly from weekly variables by aggregating all weeks commencing in a particular month to that month. </li>\n<li>  We remove all values for years with less than 10 data points.</li>\n<li>  We remove all values for time series where the only values are 0 or NA.</li>\n<li>  We do not show data for the most recent 28 days. Data covering the most recent 28 days is often adjusted and updated in the weeks following its release.</li>	0		YlOrRd		confirmed cases